Early, aggressive treatment could halt debilitating muscle disease
NCT ID NCT05832034
Summary
This study is testing if adding a treatment called intravenous immunoglobulin (IVIg) to standard steroid therapy early in the course of inflammatory muscle diseases (myositis) leads to better and faster improvement. It involves 44 adults newly diagnosed with conditions like dermatomyositis or polymyositis. The goal is to see if this 'hit-early, hit-hard' approach reduces disease activity more effectively and prevents long-term disability.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Neurology, Amsterdam UMC, location AMC
Amsterdam, North Holland, 1105 AZ, Netherlands
Conditions
Explore the condition pages connected to this study.